As Of September 2016, The Company Held Cash And Cash Equivalents Of 374.4 Million ($483.4 Million) Compared To 234.9 Million During The Same Period Last Year.

The company’s chief product is Sativex, an oromucosal spray for the treatment of multiple sclerosis, cancer pain and neuropathic pain, ailments for which doctor’s are urgently seeking non-opioid solutions. GW Pharmaceuticals has a partnership with German-based giant Bayer ( BAYRY ) for the distribution of Sativex in the UK. GWPH offers another cannabis-based product, Epidiolex, for the treatment of epilepsy. Unlike most of its peers, GWPH boasts a solid balance sheet with plenty of financial wherewithal. As of September 2016, the company held cash and cash equivalents of 374.4 million ($483.4 million) compared to 234.9 million during the same period last year. GWPH’s Quick Ratio (cash versus financial liabilities) of 5.96 is strong. The company also differs from most marijuana companies in that it faces solid growth prospects. The average analyst expectation is for the company to post year-over-year earnings growth next year of 28.2%. The stock has risen 16.15% year to date and 55.86% over the past 12 months. GWPH shares now hover at about marijuana business $129.30; the average analyst one-year price target is $154.44, for a gain of nearly 20%.

To read more visit

Comments are closed.